Identifying biomarkers for progressive supranuclear palsy
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.
List view / Grid view
Protein biomarkers in spinal fluid linked to PSP could enable earlier diagnosis and treatment for this neurological disorder.
Through multi-omics analysis, researchers find that oestrogen signalling could be a target for never-smoker lung cancer cases.
A panel of HTS assays was developed using the Transcreener platform to accelerate the development of selective helicase inhibitors.
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
The study’s findings explain the genetic differences in people’s blood pressure, which could lead to personalised medicine approaches.
A new method for a fragmentation-based identification of lipids could enable the study of cancer cells in detail not seen before.
Researchers highlight the need for considering biomarkers alongside other health outcomes, as well as the need for omic data standardisation.
Researchers have discovered potential biomarkers to identify paediatric sepsis progression stage, enabling more targeted treatment.
A new project plans to elucidate the relationship between the glucosylceramidase beta gene and Parkinson’s disease.
The guide provides examples of how Transcreener allowed rapid assay development to enable screening for kinases in innate immune pathways.
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
Researchers explored the effects of loops and 3D genome organisation on gene silencing, and found that ‘cohesinopathies’ may be linked it.
Using an AI algorithm to predict glioblastoma’s most active kinase, researchers hope for a next-generation precision therapy targeting resistant cancers.
Dr Ketan Patel, Clarivate, shares his insights about the use of Real-World Data and genomic biomarker data and discusses how researchers can use these to better detect and diagnose diseases.
Disruptions in TP53 and RB1 are key influencers that cause changes in the risk of mutations across chromosomes.